Molnupiravir (MK-4482, EIDD-2801) is an investigational oral antiviral medicine that significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.
Tag Archives: Antiviral Drugs
CORONAVIRUS PODCAST: TRACING APPS, Antiviral remdesivir’S PROMISE
The Coronapod team pick through the latest news, plus we hear from the researchers making lemonade out of lockdown lemons.
In this episode:
01:10 Can contact-tracing apps help?
Governments around the world are banking on smartphone apps to help end the spread of the coronavirus. But how effective might these apps might be? What are the risks? And how should they fit into wider public health strategies?
Editorial: Show evidence that apps for COVID-19 contact-tracing are secure and effective
13:30 Antiviral remdesivir shows promise
Early results from a US trial of the antiviral drug remdesivir suggest it shortens recovery time for patients with COVID-19. We unpick the findings.
News: Hopes rise for coronavirus drug remdesivir
16:52 One good thing
Our hosts pick out things that have made them smile in the last week, including blooming trust in scientists, cooking experiments, and a neighbourhood coming together to clap for healthcare workers.
21:34 Unexpected opportunities
We hear from three researchers making the most of lockdown, studying tiny earthquakes, building balcony-based citizen science projects, or enlisting gamers to fight the coronavirus.
Doctors Without Waiting Rooms 